Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Core Insights - Immuneering Corporation's stock declined after the release of updated data from its Phase 2a trial of atebimetinib combined with modified chemotherapy for first-line pancreatic cancer [1] Clinical Trial Results - The trial involved 34 patients with a median follow-up of over 13 months, showing an overall survival rate of 35% at 12 months for the chemotherapy regimen, compared to 64% for the atebimetinib combination [1] - At 9 months, survival was reported at 83% for the atebimetinib arm versus approximately 47% for the chemotherapy arm, and at 6 months, the rates were 94% for atebimetinib compared to 67% for chemotherapy [2] - Median progression-free survival (PFS) was 8.5 months for atebimetinib compared to 5.5 months for chemotherapy, with a confirmed overall response rate (ORR) of 39% at 12 months versus 23% for the chemotherapy group [2] Safety Profile - The combination of atebimetinib (320mg once daily) and mGnP demonstrated a favorable tolerability profile, with two categories of Grade 3 adverse events occurring in more than 10% of patients [3] Future Developments - Data from an expanded cohort of 50 pancreatic cancer patients in the atebimetinib + mGnP trial is anticipated in the first half of 2026 [4] - The company plans to initiate dosing for the pivotal Phase 3 trial (MAPKeeper 301) of atebimetinib + mGnP in mid-2026 [4] - Immuneering also expects to begin dosing the first patient in a trial combining atebimetinib with Regeneron Pharmaceuticals' Libtayo in non-small cell lung cancer in the second half of 2026 [5] - As of December 2025, the company confirmed that its cash and cash equivalents are sufficient to fund operations into 2029 [5] Stock Performance - Immuneering's shares fell by 26.53% to $6.12 during premarket trading following the announcement of the trial data [6]